Review
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2019; 11(11): 957-970
Published online Nov 15, 2019. doi: 10.4251/wjgo.v11.i11.957
Non-coding RNA in drug resistance of gastric cancer
Ya-Jun Luo, Qing-Mei Huang, Yan Ren, Zi-Lin Liu, Cheng-Fei Xu, Hao Wang, Jiang-Wei Xiao
Ya-Jun Luo, Yan Ren, Zi-Lin Liu, Cheng-Fei Xu, Hao Wang, Jiang-Wei Xiao, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, Sichuan Province, China
Ya-Jun Luo, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, China
Qing-Mei Huang, Department of Oncology, The Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China
Author contributions: Luo YJ, Huang QM did equally to this work, should be co-first author. Luo YJ and Xiao JW designed research; Luo YJ, Huang QM, Ren Y, Liu ZL, Xu CF, Wang H performed research; Luo YJ, Huang QM and Xiao JW contributed new reagents or analytic tools; Luo YJ, Huang QM and Xiao JW analyzed data; Luo YJ, Huang QM and Xiao JW wrote the paper.
Supported by National Natural Science Foundation of China (NSFC) Grant, No. 81070378, and No. 81270561; Sichuan Outstanding Youth Fund Project Grant, No. 2015JQ0060.
Conflict-of-interest statement: The authors declare that there is no conflict of interests regarding the publication of this paper.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jiang-Wei Xiao, MD, PhD, Professor, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chengdu Medical College, No. 278, Baoguang Road, Xindu District, Chengdu 610500, Sichuan Province, China. xiaojiangwei@126.com
Telephone: +86-17311394528
Received: February 26, 2019
Peer-review started: February 27, 2019
First decision: July 31, 2019
Revised: September 21, 2019
Accepted: October 3, 2019
Article in press: October 3, 2019
Published online: November 15, 2019
Processing time: 262 Days and 20.8 Hours
Abstract

Gastric cancer (GC) is the third leading cause of cancer-related mortality worldwide. The poorly prognosis and survival of GC are due to diagnose in an advanced, non-curable stage and with a limited response to chemotherapy. The acquisition of drug resistance accounts for the majority of therapy failure of chemotherapy in GC patients. Although the mechanisms of anticancer drug resistance have been broadly studied, the regulation of these mechanisms has not been completely understood. Accumulating evidence has recently highlighted the role of non-coding RNAs (ncRNAs), including long non-coding RNAs and microRNAs, in the development and maintenance of drug resistance due to their regulatory features in specific genes involved in the chemoresistant phenotype of GC. We review the literature on ncRNAs in drug resistance of GC. This review summarizes the current knowledge about the ncRNAs’ characteristics, their regulation of the genes involved in chemoresistance and their potential as targeted therapies for personalized treatment in resistant GC.

Keywords: Non-coding RNAs; Long non-coding RNAs; MicroRNAs; Drug resistance; Multidrug resistance; Gastric cancer

Core tip: Many non-coding RNAs (ncRNAs, including long non-coding RNAs and microRNAs) are dysregulated in gastric cancer (GC) and involved in many cellular and genomic process and involved in drug resistance. The acquisition of drug resistance accounts for the majority of therapy failure of chemotherapy in GC patients. This review summarizes the current knowledge about the ncRNAs’ characteristics, their regulation of the genes involved in chemoresistance of GC. These potential of ncRNAs as candidates to develop novel strategies to molecular targeted therapy or reverse the GC cell drug resistance for personalized treatment in GC.